---
title: Study To Evaluate The Impact Of Early Initiation Of Biological Treatment With Ankylosing Spondylitis
nct_id: NCT04507763
overall_status: COMPLETED
sponsor: Pfizer
study_type: OBSERVATIONAL
primary_condition: Ankylosing Spondylitis
countries: Iraq
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04507763.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04507763"
ct_last_update_post_date: 2021-10-28
last_seen_at: "2026-05-12T07:25:28.785Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Study To Evaluate The Impact Of Early Initiation Of Biological Treatment With Ankylosing Spondylitis

**Official Title:** Clinical Outcomes of Early Versus Delayed Management of Iraqi Patients With Ankylosing Spondylitis (AS) With Etanercept

**NCT ID:** [NCT04507763](https://clinicaltrials.gov/study/NCT04507763)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 763
- **Lead Sponsor:** Pfizer
- **Conditions:** Ankylosing Spondylitis
- **Start Date:** 2020-08-01
- **Completion Date:** 2020-10-01
- **CT.gov Last Update:** 2021-10-28

## Brief Summary

This study is to evaluate available data in Iraqi patients with ankylosing spondylitis on Enbrel treatment with regards to the impact of early treatment using data from the Baghdad Teaching Hospital registry

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Diagnosed AS patients.

  * 18 years old
* Did not receive previous biological treatment for any reason

Exclusion Criteria:

* Patients previously or currently treated with other biological therapies.
* Use of etanercept for less than 1 year duration.
```

## Arms

- **Patients with ankylosing spondylitis** — Iraqi patients diagnosed with ankylosing spondylitis that received Etanercept as treatment for disease

## Interventions

- **Etanercept** (DRUG) — Patients with ankylosing spondylitis as provided in real world practice

## Primary Outcomes

- **Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) Total Score at Month 12** _(time frame: Baseline, Month 12 [from the data retrieved and observed in 2 months of this study])_ — BASFI is a set of 10 questions to determine degree of functional limitation in participants with AS. Participants answered each 10 questions on a scale of 0 (no functional impairment) to 10 (maximal impairment). BASFI total score was calculated as mean of scores from 10 questions. BASFI total score ranged from 0 (no functional impairment) to 10 (maximal impairment), where higher scores meant worse condition. In this outcome measure, participants were grouped on the basis of early and delayed referral to management of AS with etanercept treatment. Early referral was considered when participants were referred to management of AS in less than or equal to (\<=) 1 year after diagnosis with AS. Participants with delayed referral to management of AS were divided into 3 groups: 1.1 to 5 years, 5.1 to 10 years and greater than (\>) 10 years after diagnosis with AS.
- **Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score at Month 12** _(time frame: Baseline, Month 12 [from the data retrieved and observed in 2 months of this study])_ — BASDAI is a set of 6 questions to determine disease activity in participant with AS. Participants answered each 6 questions on a scale of 0 (no problem) to 10 (the worst problem). The BASDAI score is calculated by computing the mean of questions 5 and 6 and adding it to the sum of questions (Q) 1-4. This score is then divided by 5. BASDAI score = (Q1 + Q2 + Q3+ Q4+ \[Q5 + Q6/2\])/5. BASDAI score ranges from 0 (best) to 10 (worst), where higher scores meant worse condition. In this outcome measure, participants were grouped on the basis of early and delayed referral to management of AS with etanercept treatment. Early referral was considered when participants were referred to management of AS in \<= 1 year after diagnosis with AS. Participants with delayed referral to management of AS were divided into 3 groups: 1.1 to 5 years, 5.1 to 10 years and \>10 years after diagnosis with AS.

## Locations (1)

- Pfizer, Baghdad, Iraq

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.pfizer|baghdad||iraq` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT04507763.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT04507763*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*